RNA — structural market context
Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.
What changed
As of the close on Nov 3. Each line shows the earlier value, the later value and their dates.
Change from the Nov 2 close to the Nov 3 close: +1.99%.
1.08× its 20-session average on Nov 3.
Includes pre- and post-market trading.
Short interest 3.7M shares (settlement Oct 15) vs 3.4M (Sep 30).
No new file loaded in this window. Latest file: settlement Oct 15, loaded Oct 27.
Latest file (settlements Oct 1–Oct 14, published Nov 3): no fails listed.
Previous file (settlements Sep 15–Sep 30, published Oct 16): 2 days with fails, largest 1K shares on Sep 15.
No new file loaded in this window.
None recorded in this window.
None recorded in this window.
RNA: what the public data shows
Each row is the latest public record we hold for RNA, with its own date and source. Figures are descriptive and delayed by their source.
RNA events and their magnitude
Latest SEC filing in the event study
8-K 7.01 · Regulation FD disclosure · filed 2026-11-02 · View on sec.gov ↗
…
RNA short interest & days to cover
FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-10-15 (20d ago)
RNA fails-to-deliver (FTD)
SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.
RNA analyst ratings
Rating actions as published by the firms, from public feeds. They are not graded here.
Frequently asked questions
Other companies in the same SEC industry: Pharmaceutical Preparations
Industry: SIC code 2834 as recorded on SEC EDGAR.
RNA: the full history
Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.
Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.